Technology
Health
Medical

Second Sight Medical Products

$0.8323
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0069 (-0.82%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell EYES and other stocks, options, ETFs, and crypto commission-free!

About

Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. Its product, the Argus II Retinal Prosthesis System, treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. Read More The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.

Employees
123
Headquarters
Sylmar, California
Founded
1998
Market Cap
64.06M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
350.22K
High Today
$0.86
Low Today
$0.8042
Open Price
$0.838
Volume
130.62K
52 Week High
$2.25
52 Week Low
$0.6351

Collections

Technology
Health
Medical
2014 IPO
US
North America

News

Seeking AlphaMar 13

Second Sight Medical Products, Inc. (EYES) CEO Will McGuire on Q4 2018 Results - Earnings Call Transcript

Second Sight Medical Products, Inc. (NASDAQ:EYES) Q4 2018 Earnings Conference Call March 13, 2019 4:30 PM ET Company Participants Lisa Wilson - Investor Relations Will McGuire - President & Chief Executive Officer John Blake - Chief Financial Officer Conference Call Participants Andrew D'Silva - B. Riley Amit Dayal - H.C. Wainwright Jeb Terry - Aberdeen Investment Management Operator Ladies and gentlemen, thank you very much for standing by. And welcome to the Second Sight Q4 2018 Results Call. Du...

135
MarketBeatFeb 28

Stock Price, News, & Analysis for Second Sight Medical Products

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. It focuses on developing new technologies to treat the population of sight-impaired individuals. The company is developing the Orion Visual Cortical Prosthesis, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or di...

127

Earnings

-$0.15
-$0.10
-$0.05
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.11 per share
Actual
-$0.10 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.